Vir Biotechnology, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$6.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$5.68M.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$382.00K.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $8.08M, a 73.21% increase year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$4.21M, a 288.68% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$2.08M.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$4.36M.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$36.29M, a 192.20% decline from fiscal 2022.
- Vir Biotechnology, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $39.36M, a 973.89% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$6.06M 10-Q · filed 2026-08-05 | $2.02M derived: sum of 3 quarters · filed 2026-08-05 | -$2.20M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$382.00K 10-Q · filed 2026-05-07 | $7.70M derived: sum of 2 quarters · filed 2026-05-07 | $3.48M derived: sum of 3 quarters · filed 2026-05-07 | $2.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $3.86M derived: sum of 2 quarters · filed 2026-02-23 | $2.98M derived: sum of 3 quarters · filed 2026-08-05 | -$2.08M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$5.09M derived: sum of 2 quarters · filed 2026-08-05 | -$10.15M 10-Q · filed 2025-11-05 | -$5.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$879.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.94M 10-Q · filed 2026-08-05 | -$1.27M derived: sum of 3 quarters · filed 2026-08-05 | $960.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$5.06M 10-Q · filed 2026-05-07 | -$395.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.84M derived: sum of 3 quarters · filed 2026-05-07 | -$7.98M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.90M derived: sum of 2 quarters · filed 2026-02-23 | -$2.92M derived: sum of 3 quarters · filed 2026-02-23 | -$4.36M 10-K · filed 2026-02-23 | -$10.19M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$7.59M derived: sum of 2 quarters · filed 2025-11-05 | -$9.02M 10-Q · filed 2025-11-05 | -$6.08M 10-Q · filed 2024-11-04 | $8.89M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | -$9.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$11.26M 10-Q · filed 2025-08-06 | -$8.26M 10-Q · filed 2024-08-01 | $6.65M derived: sum of 3 quarters · filed 2026-02-23 | -$20.24M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | -$1.43M 10-Q · filed 2025-05-08 | -$1.83M 10-Q · filed 2024-05-03 | $16.47M derived: sum of 2 quarters · filed 2026-02-23 | -$10.42M derived: sum of 3 quarters · filed 2026-02-23 | -$28.23M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$8.99M derived: sum of 2 quarters · filed 2026-02-23 | -$26.79M derived: sum of 3 quarters · filed 2026-02-23 | -$36.29M 10-K · filed 2026-02-23 | -$64.97M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | -$26.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$44.70M derived: sum of 2 quarters · filed 2024-11-04 | -$54.19M 10-Q · filed 2024-11-04 | -$3.81M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | -$17.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$27.30M 10-Q · filed 2024-08-01 | $23.08M derived: sum of 3 quarters · filed 2025-02-27 | $6.59M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$9.49M 10-Q · filed 2024-05-03 | $40.89M derived: sum of 2 quarters · filed 2025-02-27 | $24.39M derived: sum of 3 quarters · filed 2025-02-27 | $29.62M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $50.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $33.89M derived: sum of 2 quarters · filed 2025-02-27 | $39.11M derived: sum of 3 quarters · filed 2025-02-27 | $39.36M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$11.27M derived: sum of 2 quarters · filed 2023-11-03 | -$11.02M 10-Q · filed 2023-11-03 | -$5.48M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $5.47M 10-Q · filed 2023-08-04 | $11.02M derived: sum of 3 quarters · filed 2024-02-26 | $9.66M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $247.00K 10-Q · filed 2023-05-08 | $5.79M derived: sum of 2 quarters · filed 2024-02-26 | $4.43M derived: sum of 3 quarters · filed 2024-02-26 | $4.86M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $4.19M derived: sum of 2 quarters · filed 2024-02-26 | $4.61M derived: sum of 3 quarters · filed 2024-02-26 | $3.67M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$935.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.88M 10-Q · filed 2022-11-03 | $2.18M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$521.00K 10-Q · filed 2022-08-09 | $3.54M derived: sum of 3 quarters · filed 2023-02-28 | $1.79M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$943.00K 10-Q · filed 2022-05-05 | $3.12M derived: sum of 2 quarters · filed 2023-02-28 | $1.37M derived: sum of 3 quarters · filed 2023-02-28 | $4.08M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.32M derived: sum of 2 quarters · filed 2023-02-28 | $5.02M derived: sum of 3 quarters · filed 2023-02-28 | $4.47M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $965.00K derived: sum of 2 quarters · filed 2021-11-04 | $416.00K 10-Q · filed 2021-11-04 | $4.93M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.16M 10-Q · filed 2021-08-05 | $6.67M derived: sum of 3 quarters · filed 2022-02-28 | $6.13M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | -$549.00K 10-Q · filed 2021-05-06 | $3.96M derived: sum of 2 quarters · filed 2022-02-28 | $3.42M derived: sum of 3 quarters · filed 2022-02-28 | $3.70M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.97M derived: sum of 2 quarters · filed 2022-02-28 | $4.25M derived: sum of 3 quarters · filed 2022-02-28 | $4.62M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | -$544.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$258.00K derived: sum of 2 quarters · filed 2020-11-10 | $109.00K 10-Q · filed 2020-11-10 | $933.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $653.00K 10-Q · filed 2020-08-11 | $1.48M derived: sum of 3 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | $367.00K 10-Q · filed 2020-05-12 | $1.19M derived: sum of 2 quarters · filed 2021-02-25 | ||||||
| 2018-12-31 | $824.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.17M 10-K · filed 2021-02-25 | ||||||
| 2018-09-30 | $3.35M 10-Q · filed 2019-11-19 | |||||||
| 2017-12-31 | $2.60M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |